Acrivon Therapeutics, Inc.

Acrivon Therapeutics announced it will present mechanistic data and early clinical responses for its WEE1/PKMYT1 inhibitor, ACR-2316, at the AACR D3 Conference. The presentations will highlight partial responses (PRs) and durable clinical benefit in AP3-predicted tumor types, including small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), as well as endometrial cancer. ACR-2316 has also demonstrated a favorable tolerability profile, primarily limited to transient neutropenia, underscoring the effectiveness of the company's AP3-guided drug design.

Acrivon Therapeutics, Inc. announced that its stockholders approved the Amended and Restated 2022 Equity Incentive Plan at the 2026 annual meeting. This plan increases the aggregate number of shares available for equity awards by 3,000,000, bringing the total to 8,606,723 shares, with automatic annual increases. Additionally, stockholders elected Michael Tomsicek and Charles Baum as Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Acrivon Therapeutics announced that its President and CEO, Peter Blume-Jensen, will participate in a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026. The clinical-stage oncology company utilizes its proprietary Generative Phosphoproteomics AP3 platform for drug design and clinical development. Acrivon is advancing ACR-368 in a registrational Phase 2b study for endometrial cancer and ACR-2316 in a Phase 1/2 study, alongside preclinical programs.

Acrivon Therapeutics, Inc. announced the approval of an equity award to one employee under its 2023 Inducement Plan. The award consists of options to purchase 111,150 shares of common stock, granted on May 15, 2026, with an exercise price equal to the closing price on the grant date. These options will vest over time, subject to continued employment, and were approved by the Board as a material inducement for employment.

Acrivon Therapeutics reported a net loss of $19.0 million, or $(0.49) per share, for the first quarter of 2026, an improvement from the $19.7 million loss in the prior year. Total operating expenses decreased to $19.9 million. The company provided positive updates on its clinical-stage assets, ACR-368 and ACR-2316, with promising data from ongoing trials. As of March 31, 2026, cash, cash equivalents, and investments stood at $97.7 million, and the company expects its current funds, supplemented by $7.3 million from an April 2026 ATM program, to cover operating expenses for at least 12 months.

Acrivon Therapeutics reported a net loss of $19.0 million for Q1 2026, a slight improvement from $19.7 million in Q1 2025. The company highlighted significant progress in its clinical programs, including the advancement of the ACR-368 Phase 2b study with an interim analysis planned for H2 2026, and positive initial data from the ACR-2316 Phase 1/2 study showing favorable tolerability and clinical activity. Acrivon also confirmed a cash runway into Q3 2027, supported by $97.7 million in cash and $7.3 million from subsequent equity financing.

Acrivon Therapeutics reported Q1 2026 financial results and provided significant updates on its clinical oncology programs. The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for serous endometrial cancer arms in H2 2026, driven by accelerated enrollment. The ACR-2316 Phase 1/2 study is progressing towards its expansion phase, showing favorable tolerability and durable clinical activity in AP3-prioritized tumors. The company's cash, cash equivalents, and marketable securities of $97.7 million as of March 31, 2026, plus $7.3 million from subsequent equity financing, are expected to fund operations into Q3 2027.

Acrivon Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will take place virtually on Wednesday, June 17, 2026, at 1:00 PM Eastern Time. Stockholders will vote on the election of two Class I director nominees, Michael Tomsicek and Charles Baum, each for a three-year term. Additionally, the meeting includes a proposal to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Acrivon Therapeutics announced positive preclinical data for its lead assets, ACR-368 and ACR-2316, demonstrating strong synergistic effects with established anti-cancer agents. ACR-368 showed potent efficacy in combination with anti-PD-L1 and Topoisomerase 1 (Topo 1) inhibitors, while ACR-2316 synergized with anti-PD-L1. These findings support the potential for future frontline clinical development of these combinations, offering new therapeutic avenues. The data will be presented at the AACR 2026 Annual Meeting.

Acrivon Therapeutics, Inc. announced the approval of an equity award grant to one employee under its 2023 Inducement Plan. The grant, effective April 15, 2026, consists of options to purchase 111,150 shares of common stock. These options were granted as a material inducement to employment and will vest over four years, with 25% vesting on the first anniversary and monthly thereafter.